Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients

Creative Commons License

Akar S., Cetin P., KALYONCU U., KARADAĞ Ö., Sari I., Cinar M., ...Daha Fazla

ARTHRITIS CARE & RESEARCH, cilt.70, ss.1090-1094, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 70 Konu: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1002/acr.23446
  • Sayfa Sayıları: ss.1090-1094


ObjectiveApproximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients.